{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:11:51Z","timestamp":1793272311252,"version":"4.5.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Primary Sj\u00f6gren syndrome (pSS) is a systemic autoimmune disease associated with dysregulated immune cells, with no efficient therapy. There is a need to study potential therapeutic approaches.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the efficacy, safety, and immune response of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group superiority design from June 2015 to August 2017. Sixty patients, aged 18 to 70 years, were recruited from Peking University People\u2019s Hospital. Efficacy analyses were based on the intention-to-treat (ITT) principle. Data were analyzed from December 2018 to March 2020.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients with pSS were treated with LD-IL-2 or placebo for 12 weeks and accompanied by 12 weeks of follow-up.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was defined as a 3-point or greater improvement on the European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Disease Activity Index (ESSDAI) by week 24. The secondary end points included other clinical responses, safety, and changes of immune cell subsets at week 12 and 24.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Sixty patients with pSS were recruited, with 30 in the LD-IL-2 group (mean [SD] age, 47.6 [12.8] years; 30 [100%] women) and 30 in the placebo group (mean [SD] age, 51.0 [11.9] years; 30 [100%] women), and 57 completed the trial. More patients in the LD-IL-2 group (20 [66.7%]) achieved ESSDAI score reduction of at least 3 points than in the placebo group (8 [26.7%]) at week 24 (\n P<\/jats:italic>\n \u2009=\u2009.004). There were greater resolutions of dryness, pain, and fatigue in the LD-IL-2 group than placebo group at week 12 (dryness: difference, \u221218.33 points; 95% CI, \u221228.46 to \u22128.21 points;\n P<\/jats:italic>\n \u2009=\u2009.001; pain: difference, \u221210.33 points; 95% CI, \u221219.38 to \u22121.29 points;\n P<\/jats:italic>\n \u2009=\u2009.03; fatigue: difference, \u221211.67 points; 95% CI, \u221220.65 to \u22122.68 points;\n P<\/jats:italic>\n \u2009=\u2009.01). No severe adverse events were observed in either group. In addition, the LD-IL-2 group showed a significant decrease in infection compared with the placebo group (1 [3.3%] vs 9 [30.0%];\n P<\/jats:italic>\n \u2009=\u2009.006). Immunological analysis revealed that LD-IL-2 promoted an expansion of regulatory T cells and regulatory CD24\n high<\/jats:sup>\n CD27\n +<\/jats:sup>\n B cells.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n In this randomized clinical trial, LD-IL-2 was effective and well tolerated in patients with pSS, and it restored immune balance, with enhanced regulatory T cells and CD24\n high<\/jats:sup>\n CD27\n +<\/jats:sup>\n B cells.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT02464319<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.41451","type":"journal-article","created":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T11:01:42Z","timestamp":1668078102000},"page":"e2241451","source":"Crossref","is-referenced-by-count":97,"title":["Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sj\u00f6gren Syndrome"],"prefix":"10.1001","volume":"5","author":[{"given":"Jing","family":"He","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiling","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Luan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebo","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Applied Statistics and School of Statistics, Renmin University of China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute for Immunology, School of Life Sciences, Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing National Laboratory for Molecular Sciences, Key Laboratory of Polymer Chemistry & Physics of Ministry of Education, Center for Soft Matter Science and Engineering, College of Chemistry and Molecular Engineering, Peking University, Beijing, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jacob","sequence":"additional","affiliation":[{"name":"SUNY at Buffalo School of Medicine, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Julian L.","family":"Ambrus","sequence":"additional","affiliation":[{"name":"SUNY at Buffalo School of Medicine, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhai","family":"Ding","sequence":"additional","affiliation":[{"name":"Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Yu","sequence":"additional","affiliation":[{"name":"The University of Queensland Diamantina Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"},{"name":"Ian Frazer Centre for Children\u2019s Immunotherapy Research, Child Health Research Centre, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis, Peking University People\u2019s Hospital, Beijing, China"},{"name":"State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,11,10]]},"reference":[{"issue":"10","key":"zoi221171r1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome.","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi221171r2","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sj\u00f6gren syndrome: a pilot trial.","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"zoi221171r3","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s10067-016-3360-4","article-title":"A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sj\u00f6gren\u2019s syndrome.","volume":"35","author":"Kedor","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"5","key":"zoi221171r4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri3823","article-title":"The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases.","volume":"15","author":"Klatzmann","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"zoi221171r5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"issue":"7","key":"zoi221171r6","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/rheumatology\/key063","article-title":"B-cell activity markers are associated with different disease activity domains in primary Sj\u00f6gren\u2019s syndrome.","volume":"57","author":"James","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"zoi221171r7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/art.39518","article-title":"Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome.","volume":"68","author":"Nocturne","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"zoi221171r8","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.immuni.2013.09.007","article-title":"Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure.","volume":"39","author":"He","year":"2013","journal-title":"Immunity"},{"issue":"5","key":"zoi221171r9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/art.v70.5","article-title":"The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary Sj\u00f6gren\u2019s syndrome.","volume":"70","author":"Fonseca","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"zoi221171r10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/art.v73.4","article-title":"Interleukin-7\/interferon axis drives T cell and salivary gland epithelial cell interactions in Sj\u00f6gren\u2019s syndrome.","volume":"73","author":"Rivi\u00e8re","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"zoi221171r11","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome.","volume":"77","author":"Miao","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"zoi221171r12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"zoi221171r13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi221171r14","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren\u2019s syndrome.","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi221171r15","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome.","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi221171r16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR Primary Sj\u00f6gren\u2019s Syndrome Disease Activity (ESSDAI) and Patient-Reported Indexes (ESSPRI).","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"zoi221171r17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome.","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi221171r18","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-07-294249","article-title":"Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells.","volume":"117","author":"Iwata","year":"2011","journal-title":"Blood"},{"issue":"24","key":"zoi221171r20","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011003","article-title":"Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sj\u00f6gren syndrome patients: a case-control study.","volume":"97","author":"Gao","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"zoi221171r21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi221171r22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial.","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"zoi221171r23","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi221171r24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease.","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi221171r25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"zoi221171r26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41584-021-00707-x","article-title":"Interleukin-2 and regulatory T cells in rheumatic diseases.","volume":"17","author":"Kolios","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"26","key":"zoi221171r28","doi-asserted-by":"publisher","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"zoi221171r29","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.757099","article-title":"Modification of intestinal microbiota dysbiosis by low-dose interleukin-2 in dermatomyositis: a post hoc analysis from a clinical trial study.","volume":"12","author":"Zhufeng","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"17","key":"zoi221171r30","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159406","article-title":"Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation.","volume":"7","author":"Tchitchek","year":"2022","journal-title":"JCI Insight"},{"key":"zoi221171r31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/243723","article-title":"T regulatory and T helper 17 cells in primary Sj\u00f6gren\u2019s syndrome: facts and perspectives.","volume":"2015","author":"Alunno","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"5","key":"zoi221171r32","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.4049\/jimmunol.135.5.3109","article-title":"Production of interleukin 2 (IL 2) by salivary gland lymphocytes in Sj\u00f6gren\u2019s syndrome: detection of reactive cells by using antibody directed to synthetic peptides of IL 2.","volume":"135","author":"Fox","year":"1985","journal-title":"J Immunol"},{"issue":"3","key":"zoi221171r33","first-page":"497","article-title":"Interleukin 2 defect in the peripheral blood and the lung in patients with Sj\u00f6gren\u2019s syndrome.","volume":"65","author":"Miyasaka","year":"1986","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"zoi221171r34","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/ard.2009.115378","article-title":"Cytokines in Sjogren\u2019s syndrome: potential therapeutic targets.","volume":"69","author":"Roescher","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"zoi221171r35","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.immuni.2020.04.015","article-title":"Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA.","volume":"52","author":"Soni","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"zoi221171r36","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.v10.6","article-title":"Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr\/Tfh ratio in lupus.","volume":"10","author":"Liang","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"zoi221171r37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","article-title":"Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study.","volume":"23","author":"Miao","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"zoi221171r38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cyto.2008.06.005","article-title":"Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells.","volume":"44","author":"Suzuki","year":"2008","journal-title":"Cytokine"},{"key":"zoi221171r39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cyto.2016.05.017","article-title":"IL-2, IL-4, IFN-? or TNF-a enhances BAFF-stimulated cell viability and survival by activating Erk1\/2 and S6K1 pathways in neoplastic B-lymphoid cells.","volume":"84","author":"Gui","year":"2016","journal-title":"Cytokine"},{"issue":"10","key":"zoi221171r40","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kex375","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren\u2019s syndrome.","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"zoi221171r41","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/rheumatology\/keq009","article-title":"Primary Sjogren\u2019s syndrome: too dry and too tired.","volume":"49","author":"Ng","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"zoi221171r42","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm866","article-title":"Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo.","volume":"9","author":"Blattman","year":"2003","journal-title":"Nat Med"},{"issue":"4","key":"zoi221171r43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/biof.107","article-title":"Cytokine regulation of natural killer cell effector functions.","volume":"36","author":"Zwirner","year":"2010","journal-title":"Biofactors"},{"issue":"1","key":"zoi221171r44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin): expert consensus on best management practices, 2014.","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"zoi221171r27","first-page":"694","article-title":"Expression of a functional IL-2 receptor in vascular smooth muscle cells.","volume-title":"J Immunol","author":"Arumugam","year":"2019"},{"key":"zoi221171r19","unstructured":"Quick start guide. HyLown. Accessed October 4, 2022. http:\/\/powerandsamplesize.com\/Calculators\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2798245\/he_2022_oi_221171_1667309994.03292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T14:18:56Z","timestamp":1678544336000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2798245"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,11,10]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41451","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,10]]}}}